Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Global cancer stem cells therapy market 3600 synopsis, 2018 – 2032
2.2 Business trends
2.3 Region trends
2.4 Type trends
2.5 Cancer type trends
2.6 End-user trends
Chapter 3 Cancer Stem Cells Therapy Industry Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing cases of cancer
3.2.1.2 Increasing private and public initiatives
3.2.1.3 Rising awareness regarding availability of stem cell therapy
3.2.1.4 Increasing research & development programs
3.2.2 Industry pitfalls & challenges
3.2.2.1 Associated side-effects
3.2.2.2 High cost of stem cell therapy
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By cancer type
3.3.3 By end-user
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players,
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Chapter 5 Cancer Stem Cells Therapy Market Size and Forecast, By Type, 2018-2032 (USD Million)
5.1 Key trends, by type
5.2 Targeted cancer stem cells
5.3 Stem cells-based therapy
5.3.1 Allogenic stem cell
5.3.2 Autologous stem cell
Chapter 6 Cancer Stem Cells Therapy Market Size and Forecast, By Cancer Type 2018-2032 (USD Million)
6.1 Key trends, by cancer type
6.2 Breast
6.3 Lung
6.4 Colorectal
6.5 Prostrate
6.6 Stomach
6.7 Liver
6.8 Other cancer types
Chapter 7 Cancer Stem Cells Therapy Market Size and Forecast, By End-user, 2018-2032 (USD Million)
7.1 Key trends, by end-user
7.2 Hospitals
7.3 Specialty centres
7.4 Other end-users
Chapter 8 Cancer Stem Cells Therapy Market Size and Forecast, By Region, 2018-2032 (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 Rest of Middle East & Africa
Chapter 9 Company Profiles
9.1 Gamida Cells
9.2 AbbVie Inc
9.3 Astellas Pharma Inc
9.4 Novadip Biosciences
9.5 ReNeuron Group plc
9.6 Celyad
9.7 Adna GmBH
9.8 Thermo Fisher Scientific
9.9 Genentech Inc
9.10 Merck KGaA
